SRRK — Scholar Rock Holding Share Price
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 23.4 | ||
| Price to Tang. Book | 23.4 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -110.26% | ||
| Return on Equity | -123.08% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 18.82 | 33.19 | n/a | n/a | n/a | 25.05 | 161.49 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.
Directors
- David Hallal CHM (54)
- Nagesh Mahanthappa PRE (56)
- Edward Myles CFO (49)
- George Nomikos SVP
- Gregory Carven CSO (45)
- Junlin Ho GCN (42)
- Yung Chyung OTH (45)
- Kristina Burow IND (47)
- Michael Gilman IND (66)
- Joshua Reed IND (48)
- Last Annual
- December 31st, 2025
- Last Interim
- December 31st, 2025
- Incorporated
- December 18th, 2017
- Public Since
- May 24th, 2018
- No. of Shareholders
- 4
- No. of Employees
- 289
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market
- Shares in Issue
- 114,883,096

- Address
- 301 BINNEY STREET, 3RD FLOOR, CAMBRIDGE, 02142
- Web
- https://scholarrock.com/
- Phone
- +1 8572593860
- Auditors
- Ernst & Young LLP
Upcoming Events for SRRK
Scholar Rock Holding Corp Annual Shareholders Meeting
Q2 2026 Scholar Rock Holding Corp Earnings Release
Similar to SRRK
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 14:07 UTC, shares in Scholar Rock Holding are trading at $50.01. This share price information is delayed by 15 minutes.
Shares in Scholar Rock Holding last closed at $50.01 and the price had moved by +53.69% over the past 365 days. In terms of relative price strength the Scholar Rock Holding share price has outperformed the S&P500 Index by +18.47% over the past year.
The overall consensus recommendation for Scholar Rock Holding is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreScholar Rock Holding does not currently pay a dividend.
Scholar Rock Holding does not currently pay a dividend.
Scholar Rock Holding does not currently pay a dividend.
To buy shares in Scholar Rock Holding you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $50.01, shares in Scholar Rock Holding had a market capitalisation of $5.75bn.
Here are the trading details for Scholar Rock Holding:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: SRRK
Based on an overall assessment of its quality, value and momentum Scholar Rock Holding is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Scholar Rock Holding is $58.00. That is 15.98% above the last closing price of $50.01.
Analysts covering Scholar Rock Holding currently have a consensus Earnings Per Share (EPS) forecast of -$3.23 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Scholar Rock Holding. Over the past six months, its share price has outperformed the S&P500 Index by +36.66%.
As of the last closing price of $50.01, shares in Scholar Rock Holding were trading +28.52% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Scholar Rock Holding PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $50.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Scholar Rock Holding's management team is headed by:
- David Hallal - CHM
- Nagesh Mahanthappa - PRE
- Edward Myles - CFO
- George Nomikos - SVP
- Gregory Carven - CSO
- Junlin Ho - GCN
- Yung Chyung - OTH
- Kristina Burow - IND
- Michael Gilman - IND
- Joshua Reed - IND





